Suppr超能文献

CDK1 相关长链非编码 RNA 和 CXCL8 介导的肺腺癌免疫抵抗。

The CDK1-Related lncRNA and CXCL8 Mediated Immune Resistance in Lung Adenocarcinoma.

机构信息

Department of Oncology, The First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

Department of Oncology, Jinshan Hospital of the First Affiliated Hospital of Chongqing Medical University, Chongqing 400016, China.

出版信息

Cells. 2022 Aug 29;11(17):2688. doi: 10.3390/cells11172688.

Abstract

BACKGROUND

Limited therapeutic options are available for advanced LUAD without driver gene mutations. Anti-CDK therapy has shown effectiveness in several kind of cancers, however, the mechanisms still need to be elucidated.

MATERIALS AND METHODS

The lncRNA associated with CDK1 and the immunomodulatory factors that regulate CDK1 were found by bioinformatics analysis and experimental verification. The prognostic model and immune resistance mechanism of lung adenocarcinoma were revealed by single cell analysis, immune infiltration analysis, and signal pathway analysis.

RESULTS

LINC00261 was found to be an important CDK1-related lncRNA with a better prognosis in LUAD. In addition, high CDK1 expression indicates a poor immunotherapy response, which may be associated with overexpression of CXCL8. CXCL8 decreased in patients who were immunotherapy-responsive but increased in patients who were immunotherapy-resistant. Signaling pathway analysis suggested that increased CXCL8 and decreased LINC00261 may participate in hypoxia-induced tumor angiogenesis and cause a poor prognosis for the patients. CXCL8 and CDK1 may change G2-M transformation and EMT and promote tumor proliferation.

CONCLUSION

This study explained that LINC00261, CDK1, and CXCL8 may have a mutual regulation relationship, which affects the occurrence of LUAD and the efficacy of immunotherapy.

摘要

背景

晚期 LUAD 缺乏驱动基因突变的治疗选择有限。抗 CDK 治疗已在多种癌症中显示出疗效,但机制仍需阐明。

材料和方法

通过生物信息学分析和实验验证,找到了与 CDK1 相关的 lncRNA 和调节 CDK1 的免疫调节因子。通过单细胞分析、免疫浸润分析和信号通路分析,揭示了肺腺癌的预后模型和免疫抵抗机制。

结果

发现 LINC00261 是一种重要的与 CDK1 相关的 lncRNA,在 LUAD 中具有较好的预后。此外,高 CDK1 表达预示着免疫治疗反应较差,这可能与 CXCL8 的过表达有关。在免疫治疗反应良好的患者中,CXCL8 减少,而在免疫治疗耐药的患者中,CXCL8 增加。信号通路分析表明,增加的 CXCL8 和减少的 LINC00261 可能参与缺氧诱导的肿瘤血管生成,并导致患者预后不良。CXCL8 和 CDK1 可能改变 G2-M 转化和 EMT,促进肿瘤增殖。

结论

本研究表明,LINC00261、CDK1 和 CXCL8 可能存在相互调节关系,影响 LUAD 的发生和免疫治疗的疗效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/d948/9454767/c5f2fd9f8cd3/cells-11-02688-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验